Basic Information
Kentera (previously Oxybutynin Nicobrand)
Regulatory Information
EMEA/H/C/000532
Authorised
June 15, 2004
23
April 8, 2025
Company Information
the netherlands
Teva B.V. Swensweg 5 2031 GA Haarlem
Teva Pharma B.V.
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Kentera. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Kentera.